Lucia Ruiz
Valencia, VC, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Risk of symptomatic leishmaniasis in patients with inflammatory bowel disease receiving biologic therapy in an endemic Mediterranean region: a population-based case-control study.
Journal: Journal of Crohn's & colitis
Published: June 08, 2026
Long-term use of subcutaneous infliximab biosimilar CT-P13 in patients with inflammatory bowel disease in clinical practice.
Journal: Revista espanola de enfermedades digestivas
Published: January 29, 2026
Leishmaniasis in Patients With Inflammatory Bowel Disease: A National Multicenter Study of GETECCU.
Journal: United European gastroenterology journal
Published: September 05, 2024
Subcutaneous Infliximab Cutoff Points in Patients With Inflammatory Bowel Disease: Data From the ENEIDA Registry.
Journal: Journal of Crohn's & colitis
Published: August 22, 2024
Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study.
Journal: Alimentary pharmacology & therapeutics
Published: February 07, 2023
Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study.
Journal: Biomedicines
Published: July 29, 2022
Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study.
Journal: Journal of Crohn's & colitis
Published: May 08, 2019
Endoscopic recommendations for colorectal cancer screening and surveillance in patients with inflammatory bowel disease: Review of general recommendations.
Journal: World journal of gastrointestinal endoscopy
Published: January 28, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026